Altogether, these results indicated that shAPE1‐loaded RCSC‐EVs could reduce the Erlotinib resistance of NSCLC cells by activating the IL‐6/STAT3 signalling. The gene discussed is STAT3; the disease is non-small cell lung carcinoma.